India’s opportunity to lead next generation injectable drug innovation
Dr Ankur Shah, Chairman & Managing Director, Invengene shares insights on India’s growing strength in injectables and its shift toward complex drug delivery systems
India is rapidly evolving into a global hub for generic injectable drugs, driven by rising disease burden, cost efficient manufacturing, and strong pharmaceutical exports. The generic injectable market in India was valued at Rs. 25,965 crore (US$ 3.0 billion) in 2024 and is projected to grow at a compound annual growth rate of 10.28 percent to reach Rs. 65,778 crore (US$ 7.6 billion) by 2033. The growing demand for affordable medicines, particularly across emerging markets, continues to strengthen India’s role as a leading supplier of injectable drugs. With nearly 40 percent of generic drugs supplied to the United States originating from India, the country’s leadership in this space is backed by robust manufacturing capabilities, strong export infrastructure, and evolving healthcare needs.
The global pharmaceutical landscape is witnessing a clear shift toward more sophisticated drug delivery approaches. Conventional injectables are gradually being complemented by complex formulations such as long acting injectables, depot based therapies, and biologics. These innovations are designed to deliver sustained therapeutic benefits, reduce the frequency of dosing, and improve overall patient adherence. This is particularly significant in the management of chronic conditions, where long term treatment consistency is essential for better clinical outcomes. As healthcare systems across the world increasingly prioritize patient centric care and efficiency, demand for advanced injectable solutions continues to grow.
This shift presents a significant opportunity for India to move beyond its traditional focus on generics and participate in higher value segments of the pharmaceutical market. Complex injectables require advanced formulation expertise, specialized manufacturing infrastructure, and stringent quality standards. Indian pharmaceutical companies are steadily strengthening capabilities across these areas, positioning themselves to compete in global markets that demand both scale and sophistication. Expanding innovation-driven therapies not only enhances competitiveness but also enables the creation of differentiated and sustainable value.
Collaboration will be a critical driver of this transformation. Stronger partnerships between industry and academia can accelerate innovation by combining scientific research with practical application. India’s academic and research institutions have a solid foundation in scientific discovery, and closer alignment with industry can help translate this into commercially viable and clinically impactful therapies. Such collaboration can support the development of new drug delivery technologies, streamline clinical research, and ensure faster progression from concept to patient access.
Regulatory progress and infrastructure development will also play an essential role. Continued efforts to strengthen regulatory frameworks, align with global standards, and improve approval timelines will support the growth of complex injectable development. At the same time, investments in advanced manufacturing capabilities such as aseptic processing, high containment systems, and automation will be necessary to meet the quality and safety requirements associated with next generation therapies.
In parallel, supportive policy measures can further accelerate this momentum. Encouraging innovation through funding initiatives, incentives, and public private partnerships can help mitigate risks and foster long-term investment in advanced drug development. As global demand for complex injectables continues to rise, India has the opportunity to position itself as a trusted partner for both development and manufacturing.
In conclusion, India is well placed to transition from a volume driven pharmaceutical hub to a leader in innovation led injectable therapies. By building on its existing strengths, deepening collaboration, and continuing to invest in regulatory and technological advancements, the country can play a significant role in advancing next generation drug delivery and improving patient outcomes on a global scale.
